FIGURE 2.
Progression-free survival (A) and overall survival (B) for patients with adenoid cystic carcinoma (ACC) and non-ACC malignant salivary gland tumors treated with gefitinib.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.